MAP3K14 and obesity due to melanocortin 4 receptor deficiency: Finally, the notion of whether patients with MHO should be approached differently remains a controversial clinical debate.64 Recent data suggest that these individuals may be in a transient physiological state along a progression to obesity-related diseases and should seek therapeutic lifestyle changes.65,66 Participants with obesity frequently display histological evidence of chronic low-grade inflammation in various organ systems, particularly hepatic and adipose tissues as well as plasma elevation in hs-CRP19 that may contribute to cardiometabolic diseases.